GSK posts positive headline results from phase III trial for Gepotidacin in uncomplicated urogenital gonorrhoea

Chris Corsico, Senior Vice President, Development, GSK, said, “With rising incidence rates and concern around growing resistance to existing treatments, gonorrhoea poses a threat to public health globally. These positive headline results demonstrate the potential for gepotidacin to provide a novel oral treatment option in the face of rising resistance and for patients who cannot take other treatments due to allergies or intolerance.”

Gonorrhoea is a sexually transmitted infection caused by bacteria called Neisseria gonorrhoeae. It has been estimated that there are 82 million new cases globally each year. In the United States, rates of reported gonorrhoea have increased 118% from 2009 to 2021, with 648,056 cases being reported to the US Centers for Disease Control and Prevention (CDC) in 2022. Gonorrhoea affects both men and women and if left untreated or inadequately treated, it can lead to infertility and other sexual and reproductive health complications. It also increases the risk of HIV infection.

The safety and tolerability profile of gepotidacin in the EAGLE-1 phase III trial was consistent with results seen in gepotidacin phase I and II trials.

Detailed results from the EAGLE-1 trial will be presented at an upcoming scientific meeting and shared with global health authorities.

GSK is also developing gepotidacin for the potential treatment of uncomplicated urinary tract infections (uUTI). Positive phase III data from the EAGLE-2 and EAGLE-3 trials were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen in April 2023, and subsequently published in The Lancet. If approved, gepotidacin could be the first in a new class of oral antibiotics in uUTI in over 20 years.

The development of gepotidacin has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement number HHSO100201300011C and with federal funds awarded by the Defense Threat Reduction Agency under agreement number HDTRA1-07-9-0002.